Probiotic intervention benefits multiple neural behaviors in older adults with mild cognitive impairment

Yuzhe Fei1, Ruiru Wang1, Jiachun Lu2

  • 1School of Public Health, Chengdu Medical College, Chengdu, Sichuan, PR China.

Geriatric Nursing (New York, N.Y.)
|March 29, 2023
PubMed

Insights

Probiotic supplements improved cognitive function and sleep quality in older adults with mild cognitive impairment (MCI). This suggests probiotics may be a viable strategy for managing MCI, potentially through gut microbiota modulation.

Area of Science:

  • Neuroscience
  • Gastroenterology
  • Gerontology

Background:

  • Probiotics have shown cognitive benefits in Alzheimer's disease patients.
  • The efficacy of probiotics for mild cognitive impairment (MCI) in older adults remains under investigation.

Purpose of the Study:

  • To investigate the effects of probiotic supplementation on cognitive function and neural behaviors in older adults diagnosed with MCI.
  • To explore the potential mechanisms, including gut microbiota changes, underlying these effects.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 42 MCI patients (age > 60).
  • Participants received either probiotic or placebo for 12 weeks.
  • Cognitive function, sleep quality, gut microbiota composition, and serological indicators were assessed pre- and post-intervention.

Main Results:

  • The probiotic group exhibited significant improvements in cognitive function compared to the placebo group.
  • Sleep quality was also enhanced in the probiotic intervention group.
  • Changes in gut microbiota composition were observed and correlated with cognitive improvements.

Conclusions:

  • Probiotic supplementation is effective in enhancing cognitive function and sleep quality in older adults with MCI.
  • Modulation of the gut microbiota appears to be a key mechanism underlying these benefits.
  • Probiotics offer a promising avenue for the clinical prevention and treatment of MCI.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
178
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
232
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
172
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
557